control of the immune response
CTLA-4 competes with
CD28 for B7
-CTLA-4 causses an inhibitory response
PD-1
inhibitory receptor found on cytotoxic T cells
-it interacts with PD-L1 found on tumor cells and PD-L2 found on dendritic cells and macrophages thereby inhibiting the immune response
pembrolizumab and nivolumab
-anti-PD-1 checkpoint inhibitors
activation induced cell death
-activated T cells develop Fas Ligand that interacts with Fas normally presents on t cells results in apoptosis
T regulatory cells
-produce IL-10 and TGFbeta which supress T cells
IFN gama inhibits
TH2 cells
-produced by TH1
IL-4 inhibits
- produced by TH2
immunological tolerance
- failure to induce specific immunity to that antigen
self tolernce
peripheral tolerance
-cells that escape central olerance are dealt with by mechanisms of peripheral tolerance. This involves clonal deletion and clonal anergy
clonal deletion
-how is this mediated
clonal anergy
-absence of co-stimulatory signals especially B7-CD28
adult tolerance
autoimmune diseases
autoimmune hemolytic anemia
- blood film shows broken and fragmented red cells typical of hemolytic anemia
immunological factors that could give rise to autoimmunity
super antigens
defective T cell regulation
- CTLA-4: competes with CD28 for B7, if CTLA-4 is defective then there will be uncontrolled activation of the T cell
genetic factors of autoimmunity
microbial factors in AI
Rheumatic fever
-caused by a strep infection that turns someones own immune system against them (molecular mimicry)
hormonal factors of AI
damage to the tissues in AI may be mediated by